Aspirin prevents adhesion of T lymphoblasts to vascular smooth muscle cells  by Yotsui, Takamori et al.
FEBS Letters 581 (2007) 427–432Aspirin prevents adhesion of T lymphoblasts to vascular
smooth muscle cells
Takamori Yotsuia, Osamu Yasudaa,*, Hidenobu Kawamotoa, Masayoshi Higuchia,
Yukana Chiharaa, Eiji Umemotob, Toshiyuki Tanakab, Masayuki Miyasakab,
Hiromi Rakugia, Toshio Ogiharaa
a Department of Geriatric Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
b Laboratory of Immunodynamics, Department of Microbiology and Immunology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka,
Suita, Osaka 565-0871, Japan
Received 24 November 2006; revised 21 December 2006; accepted 22 December 2006
Available online 12 January 2007
Edited by Beat ImhofAbstract In the development of atherosclerosis, inﬂammatory
cells adhere to and migrate into the vascular walls by interacting
with vascular smooth muscle cells. To investigate the mechanism
of aspirin’s anti-atherogenic activity, we examined whether aspi-
rin inhibits the adhesion of lymphocytes to human aortic smooth
muscle cells (AoSMC). Aspirin inhibited T-cell adhesion to
AoSMC activated by interleukin 1b (IL-1b) in a dose-dependent
manner. Antibodies to the adhesion molecules ICAM-1 or
VCAM-1, but not to E-selectin, prevented T-cell adhesion.
ICAM-1 and VCAM-1 expression stimulated by IL-1b was re-
duced by the treatment with aspirin, whereas the expression of
E-selectin was unaﬀected. Nuclear factor jB (NF-jB) activity
was enhanced by IL-1b and reduced by aspirin, indicating that
decreased ICAM-1 and VCAM-1 expression was due to reduced
NF-jB activity.Thus, aspirin inhibits the adhesion of Jurkat T
cells to IL-1b-activated AoSMC by reducing NF-jB activity
and decreasing expression of ICAM-1 and VCAM-1, and may
prevent the development of atherosclerosis.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Atherosclerosis; Anti-inﬂammatory activity;
Aspirin; ICAM-1; VCAM-11. Introduction
Atherosclerosis was once considered to be a disorder that
resulted from abnormal lipid metabolism, however, recent
studies have demonstrated that it is caused by chronic inﬂam-
mation in vascular walls, the subsequent release of various
cytokines, and the proliferation of smooth muscle cells, which
produce the extracellular matrix.
The earliest stage of atherosclerotic development is the per-
turbation of vascular endothelial function, which may beAbbreviations: AoSMC, aortic smooth muscle cells; IL-1b, interleukin
1b; VSMC, vascular smooth muscle cells; NF-jB, nuclear factor jB;
FITC, ﬂuorescein isothiocyanate; FACS, ﬂuorescence-activated cell
sorter analysis; MFI, mean ﬂuorescence intensity; ASA, acetyl salicylic
acid
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caused by smoking, infection of microorganisms such as Chla-
mydia pneumoniae, altered shear stress, hypertension, and dia-
betes mellitus [1]. Endothelial dysfunction is accompanied by
the impaired nitric oxide production via the action of endothe-
lial nitric oxide synthase. Decreased level of nitric oxide
promotes atherosclerosis through numerous pathways, such
as increased reactive oxygen species, vascular constriction,
proliferation of smooth muscle cells, and lymphocyte adhesion
[2,3].
Vascular smooth muscle cells (VSMC) also play an impor-
tant role in the development of atherosclerosis [4]. VSMC
migrate, proliferate, and produce extracellular matrix compo-
nents in atherosclerotic plaques. The death of VSMC and their
decrease in atherosclerotic plaques lead to the formation of
vulnerable plaques. These plaques are susceptible to rupture,
and trigger cardiovascular diseases through the thrombotic
embolization of coronary arteries [5]. Indeed, the apoptotic
death of VSMC in coronary arteries is increased in patients
with unstable angina rather than those with stable angina [6,7].
In addition to VSMC and extracellular matrix and lipid
deposits, inﬂammatory cells such as macrophages and T lym-
phocytes are present in atherosclerotic plaques. Macrophages
recognize and bind to oxidized LDL via scavenger receptors,
and are transformed into foam cells through the uptake of oxi-
dized LDL. T lymphocytes are present in every stage of athero-
sclerotic development, and are pathologically a fundamental
component of both early and late stages of atherosclerosis
[1,8]. Oligoclonal proliferation of T cells in vulnerable athero-
sclerotic plaques was recently reported [9,10].
Interleukins are produced not only by leukocytes, but also
by endothelial cells and VSMC in vascular walls during inﬂam-
mation. Many interleukin family members have been identiﬁed
and implicated in the development of atherosclerosis. Pro-
inﬂammatory interleukin, IL-1b, is one of the cytokines con-
sidered instrumental in the development of atheroscleorosis,
since it exerts pro-inﬂammatory eﬀects on endothelial cells,
VSMC, and macrophages [11]. The binding of IL-1b to IL-1
receptor type I activates intracellular signal transduction
through the p38 mitogen-activated protein kinase cascade,
which culminates in the nuclear translocation of the transcrip-
tion factor, nuclear factor jB (NF-jB).
Expression of adhesion molecules, such as ICAM-1 and
VCAM-1, is increased in coronary atheroscleorotic tissueblished by Elsevier B.V. All rights reserved.
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increase the expression of ICAM-1, VCAM-1, and E-selectin
through the activation of NF-jB [14]. These cytokines also
enhance the production of monocytic chemo-attractant pro-
tein-1, a chemokine [15]. The increased expression of cell adhe-
sion molecules is important, since it causes inﬂammatory cells
to be targeted to the injured arteries [1,16].
Aspirin is an anti-inﬂammatory drug that has been used for
the primary and secondary prevention of atherosclerotic dis-
eases for two decades. It decreases the onset of cardiovascular
diseases by 20–25% [17]. Aspirin is used clinically at low and
high doses. A low dose of aspirin has anti-thrombotic activity
by blocking COX-1 activity and inhibiting prostaglandin sig-
nal transduction. A high dose of aspirin has anti-inﬂammatory
activity unrelated to the inhibition of prostaglandin synthesis.
Aspirin decreases the adhesion of macrophages to endothe-
lial cells and VSMC [18,19]; however, its eﬀect on the adhesion
of T lymphocytes to VSMC has not been well studied. In this
study, we report that aspirin inhibits the adhesion of Jurkat T
cells to human aortic smooth muscle cells (AoSMC) treated
with the inﬂammatory cytokine IL-1b by reducing the expres-
sion of ICAM-1 and VCAM-1.2. Materials and methods
2.1. Cell culture
AoSMC were purchased from Kurabo (Osaka, Japan) and cultured
in HuMedia-SG2 (Kurabo) supplemented with 10% fetal bovine serum
(FBS) in 5% CO2 atmosphere. Cultured cells from passage 4 to 12 were
used for experiments. Jurkat T cells (human T cell lymphoblasts) were
maintained in RPMI 1640 medium (Nichiken Biomedical, Tokyo,
Japan) supplemented with 10% FBS. Human recombinant IL-1b was
purchased from Sigma (Saint Louis, MO, USA) and used at a concen-
tration of 100 ng/ml. Aspirin was obtained from Sigma and used at the
indicated concentrations.
2.2. Cell adhesion assay
AoSMC were cultured using 96-well plates. Anti-human E-selectin
(68-5H11) and anti-human VCAM-1 (51-10C9) antibodies were pur-
chased from BD Pharmingen (San Diego, CA, USA); anti-human
ICAM-1 (HA58) and Mouse IgG1 j Isotype Control antibodies were
from eBioscience (San Diego, CA, USA).
For adhesion molecule inactivation experiments, anti-ICAM-1, anti-
VCAM-1, and anti-E-selectin monoclonal antibodies were added at
20 lg/ml, incubated for 30 min, and then washed three times with cul-
ture medium before the addition of T cells. Cell adhesion was assayed
as described previously [20,21]. Brieﬂy, Jurkat T cells, 5 · 105 cells/ml
in culture medium, were ﬂuorescently labeled with 2 lM biscarboxy-
ethyl-carboxyﬂuorescein acetoxymethylether (BCECF-AM) for
30 min at 37 C. Fluorescently-labeled T cells were added to the adher-
ent cells in 96-well plates, incubated at 37 C for 30 min, and then each
well was ﬁlled with culture medium and covered with paraﬁlm. Air
bubbles were excluded. The 96-well plates were then inverted and incu-
bated for 30 min in order to remove unattached T cells. After removing
the medium, 100 ll of 1% NP40 in PBS was added. Fluorescence inten-
sity was measured at 530 nm with a 490 nm excitation wavelength by
Wallac 1420 ARVOMX/Light (Perkin–Elmer, Tokyo, Japan).
2.3. AoSMC viability assay in the presence of ﬁxed Jurkat T cells
AoSMC were cultured using 96-well plates. Jurkat T cells were ﬁxed
at 4 C with 1% paraformaldehyde in PBS, and co-incubated with
AoSMC. Cell viability was quantiﬁed using MTT assay kit (Sigma),
according to the manufacturer’s instructions.
2.4. Flow cytometry
AoSMC were incubated with antibodies at 20 lg/ml at 4 C
for 30 min, and ﬂuorescein isothiocyanate (FITC)-labeled rat anti-mouse IgG (eBioscience) was used as the secondary antibody.
AoSMC were washed once in PBS between steps. After a ﬁnal wash
in PBS, cells were analyzed in a Becton–Dickinson FAC Scan ﬂow
cytometer.2.5. NF-jB activity assays
NF-jB activity was assessed using the dual-luciferase reporter assay
system (Promega, Madison, WI, USA). Brieﬂy, AoSMC were seeded
into 24-well plates and transfected with 1 lg of a NF-jB reporter plas-
mid and 100 ng of a control renilla-luciferase vector, pRL-TK, using
lipofectamine reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions, and then incubated for 6 h in
500 lL culture medium. After removal of lipofectamine in the medium,
IL-1b and aspirin were added and cells were harvested 3 h later. The
luciferase activity was measured using the dual-luciferase assay system
(Promega) and a luminometer Wallac 1420 ARVOMX/Light (Perkin–
Elmer). The ﬁreﬂy-luciferase activity of NF-jB was normalized to re-
nilla-luciferase activity and expressed as a ‘‘fold’’ induction compared
with the control value.2.6. Statistical analysis
Statistical analysis was performed using the Student’s unpaired t-
test. Results were expressed as the means ± S.D.3. Results
3.1. Cytotoxic eﬀects of aspirin
In order to investigate the toxicity of aspirin on AoSMC in
culture, cells were cultured in the presence of various concen-
trations of aspirin for 48 h. The survival ratio of AoSMC
was not inﬂuenced by aspirin up to 100 lg/ml. We, therefore,
studied the eﬀect of aspirin on cell adhesion at 100 lg/ml in
the following experiments.3.2. Aspirin inhibits the adhesion of lymphocytes to AoSMC
Jurkat T cells were cultured and ﬂuorescently labeled with
BCECF-AM. Labeled cells were incubated with AoSMC, and
adherent Jurkat T cells were assayed. Adhesion of T lympho-
blasts to VSMC is increased by IL-1b in a dose-dependent
manner in the dose range of 0–100 ng/ml [22]. Therefore,
we incubated AoSMC with IL-1b at the concentration of
100 ng/ml. There were few adherent cells on AoSMC without
IL-1b; however, in the presence of IL-1b, many Jurkat T cells
adhered to the layer of AoSMC (Fig. 1A). The ﬂuorescence
assay revealed that Jurkat T cell adhesion to AoSMC was
increased approximately 8.0 folds (Fig. 1B), whereas, the
viability of AoSMC was increased 1.49 ± 0.23 folds in the
presence of IL-1b (average of the mean ± S.D. of three sets
of experiments), indicating that the increased adhesion of
Jurkat T cells was not simply caused by the increased viabil-
ity of AoSMC. We treated IL-1b-stimulated AoSMC with
aspirin for 24 h before the addition of ﬂuorescently-labeled
Jurkat T cells. The adhesion of the T cells to AoSMC was
reduced by the preincubation of AoSMC with aspirin
(Fig. 1A). The ﬂuorescence assay of the lymphocyte adhesion
also showed a signiﬁcant decrease of T-cell adhesion with
aspirin (Fig. 1B). Lower concentrations of aspirin also
inhibited Jurkat T cell adhesion (Fig. 1C). The inhibitory
eﬀect of aspirin in this assay was dose-dependent. Treatment
of AoSMC with aspirin for 24 and 48 h had no statisti-
cally signiﬁcant diﬀerence in inhibitory eﬀects (data not
shown).
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Fig. 1. Aspirin (acetyl salicylic acid: ASA) attenuates the adhesion of Jurkat T cells to AoSMC in a dose-dependent manner. (A) Representative
photographs of Jurkat T cells adhering to AoSMC. AoSMC were cultured with IL-1b for two days. ASA was then added at 100 lg/ml and cells were
cultured for an additional 24 h. Representative light microscopic images (upper) and the corresponding ﬂuorescent microscopic images (bottom) are
shown. (B) Quantitative measurement of Jurkat T cell adhesion to AoSMC. Adhesion of BCECF-AM-labeled Jurkat T cells was assessed using
ﬂuorescence spectrometry. Fluorescence of the input cells was used as the 100% value. Values are the means ± S.D. of three experiments with
independent cultures. (C) ASA shows a dose-dependent inhibition of Jurkat T cell adhesion to IL-1b-activated AoSMC monolayers. Data are
expressed as the percent variation compared with T-lymphoblast adhesion in vehicle alone (control). Values are the means ± S.D. of ﬁve independent
experiments. Asterisks denote P < 0.05 versus control.
T. Yotsui et al. / FEBS Letters 581 (2007) 427–432 4293.3. Anti-ICAM-1 and anti-VCAM-1 antibodies inhibit adhesion
of Jurkat T cells to AoSMC
To investigate the role of adhesion molecules on AoSMC in
adhesion to Jurkat T cells, AoSMC stimulated by IL-1b were
incubated with adhesion molecule-speciﬁc antibodies before
the addition of Jurkat T cells. The pretreatment of AoSMC
with antibodies to ICAM-1 or VCAM-1 produced a statisti-
cally signiﬁcant decrease in lymphocyte adhesion, whereas pre-
treatment with the antibody to E-selectin did not inﬂuence
adhesion (Fig. 2). The combination of antibodies to ICAM-1
and to VCAM-1 had an additive eﬀect, and the addition of
aspirin to ICAM-1 and VCAM-1 antibodies together had no
further eﬀect. These ﬁndings indicate that both ICAM-1 andVCAM-1 play important roles in lymphocyte adhesion to
AoSMC, while E-selectin does not, and that the prevention
of Jurkat T cell adhesion by aspirin is mainly due to the
suppression of ICAM-1 and VCAM-1.3.4. Aspirin inhibits the AoSMC expression of ICAM-1
and VCAM-1
To determine the eﬀects of aspirin on the expression of adhe-
sion molecules on AoSMC, ﬂuorescence-activated cell sorter
analysis (FACS) was performed. IL-1b enhanced ICAM-1
and VCAM-1 expression, which was reduced by the treatment
of AoSMC with aspirin for 24 h (Fig. 3A). Mean ﬂuorescence
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Fig. 2. Aspirin (ASA) and antibodies to ICAM-1 and VCAM-1
prevent Jurkat T cell adhesion to aortic smooth muscle cells (AoSMC).
Smooth muscle cells were cultured for three days in medium containing
IL-1b, followed by the addition of BCECF-AM-labeled T-lympho-
blasts. ASA (100 lg/ml) was added 24 or 48 h before adding Jurkat T
cells. Blocking antibodies (20 lg/ml) were added 0.5 h before adding
Jurkat T cells. Adhesion of BCECF-AM-labeled Jurkat T cells was
assessed using ﬂuorescence spectrometry. Values are the means ± S.D.
of ﬁve experiments. Asterisks denote P < 0.05 versus vehicle alone.
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(A) Representative histograms of adhesion molecule expression on AoSMC.
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430 T. Yotsui et al. / FEBS Letters 581 (2007) 427–432intensity (MFI) measurements revealed that aspirin inhibited
approximately 30% of the increase of ICAM-1 expression by
IL-1b, whereas it inhibited almost 90% of the VCAM-1 in-
crease (Fig. 3B). The degree of reduction of ICAM-1 did not
diﬀer between aspirin treatment for 24 and 48 h (data not
shown), consistent with the data that lymphocyte adhesion
was similar when cells were treated with aspirin for either 24
or 48 h. The expression of E-selectin was not increased by
IL-1b, and aspirin did not alter the expression level of E-selec-
tin of AoSMC treated with IL-1b.
3.5. Aspirin reduces NF-jB activity in AoSMC
The expression of ICAM-1 and VCAM-1 is regulated by
NF-jB, a transcription factor with DNA-binding activity that
is induced by a variety of stimuli. The NF-jB activity of
AoSMC was markedly increased by stimulation with IL-1b.
Treatment with aspirin reduced the elevated NF-jB activity
by IL-1b (Fig. 4). These ﬁndings indicate that the inhibition
of ICAM-1 and VCAM-1 expression by aspirin is at least
partly due to the reduction of NF-jB activity in AoSMC.
3.6. Aspirin increases the viability of AoSMC
In order to investigate whether aspirin aﬀects the stability of
atherosclerotic plaques, we assessed the eﬀect of aspirin on
AoSMC viability. AoSMC were cultured in the presence or
absence of aspirin for 24 h, and then co-incubated with ﬁxed104
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say. Expression of adhesion molecules was assessed by FACS analysis.
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Fig. 4. Aspirin (ASA) suppresses NF-jB activity in aortic smooth
muscle cells (AoSMC). AoSMC were cultured for 3 h in medium
containing IL-1b with or without ASA (100 lg/ml), followed by the
NF-jB activity assay. Control; untreated AoSMC; IL-1b: AoSMC
treated with IL-1b; IL-1b + ASA: AoSMC treated with IL-1b and
ASA. Values are the means ± S.D. of three independent experiments.
*P < 0.05.
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viability of AoSMC by approximately 20% (data not shown).
This ﬁnding suggests that aspirin stabilizes atherosclerotic
plaques by increasing smooth muscle cells.4. Discussion
Recently, an increasing number of studies report that lym-
phocyte invasion into the atherosclerotic arteries triggers the
rupture of plaques [9,10,23,24]. In experiments in which lym-
phocytes were co-incubated with VSMC derived from human
aneurism, co-cultured helper T cells stimulated the prolifera-
tion of VSMC, whereas natural killer T cells induced VSMC
apoptosis [9]. The proliferation of VSMC contributes to the
formation of atherosclerotic plaques, and apoptosis of VSMC
increases the vulnerability of plaques. In this study, aspirin in-
creased the viability of AoSMC co-incubated with Jurkat T
cells, suggesting that aspirin may prevent the formation of vul-
nerable plaques, which are prone to rupture and cause cardio-
vascular events. The increase of AoSMC viability by aspirin is
considered to be due to the prevention of Jurkat T cell adhe-
sion, because aspirin itself does not have proliferative or
anti-proliferative activity for AoSMC at the concentrations
used in this study.
TNF-a and IL-1b increase the expression of ICAM-1,
VCAM-1 and E-selectin through the activation of NF-jB in
vascular endothelial cells [18,25–27]. In contrast, E-selectin
expression is not increased by IL-1b in human pulmonary
VSMC [28]. This is consistent with our ﬁndings that E-selectin
expression was not increased by IL-1b in AoSMC, although
ICAM-1 and VCAM-1 expression was stimulated.
Aspirin inhibited the expression of ICAM-1 by approxi-
mately 30%, while it inhibited VCAM-1 expression almost
completely. However, aspirin’s inhibition of Jurkat T cell
adhesion could be attributed to both of these adhesion mole-
cules, since the adhesion of Jurkat T cells was more strongly
blocked by anti-ICAM-1 antibody than by anti-VCAM-1.
Further, Jurkat T cell adhesion was inhibited in an additive
manner using both adhesion molecule antibodies, indicating
that both ICMA-1 and VCAM-1 contribute to Jurkat T cell
adhesion to AoSMC. The addition of aspirin to both anti-ICAM-1 and anti-VCAM-1 antibodies did not show further
inhibitory eﬀect of Jurkat T-cell adhesion. This indicates that
the inhibitory action of aspirin on the adhesion of Jurkat T
cells appears to be mainly due to the inhibition of ICAM-1
and VCAM-1, although other adhesion molecules may also
contribute to this eﬀect.
Aspirin inhibits the phosphorylation of IjB, thereby pre-
venting the degradation of the inhibitory protein IjB and
maintaining NF-jB in an inactive form in endothelial cells
[18,29] However, the action of aspirin on VSMC has not been
fully elucidated. In the present study, we showed that aspirin
inhibits NF-jB activity, which in turn regulates the transcrip-
tion of many genes, including ICAM-1 and VCAM-1.
Therapeutic doses of aspirin exhibit two types of actions,
depending on the dose. At low therapeutic doses, aspirin is
an eﬀective inhibitor of the cyclooxygenase pathway and pros-
taglandin-mediated signaling, and at higher therapeutic doses,
aspirin has anti-inﬂammatory eﬀects that are independent of
the inhibition of prostaglandin synthesis. Our study demon-
strated, for the ﬁrst time, that aspirin inhibits the adhesion
of T lymphocytes to VSMC through the inhibition of NF-jB
activity, and therefore also increases the viability of VSMC.
Prevention of VSMC death in plaques leads to an increase in
extracellular matrix production. It has been reported that
VSMC are abundant in stable atherosclerotic plaques [30].
Therefore, aspirin may contribute to the formation of stable
plaques, suggesting a novel therapeutic role for aspirin in sta-
bilizing vulnerable atherosclerotic plaques.
It is not easy to estimate the concentration of aspirin and its
derivatives in blood, because aspirin is rapidly degraded by
non-speciﬁc esterases. Hydrolysis occurs mainly in the liver
and stomach, and 68% of the administrated aspirin reaches
the systemic circulation [31]. In humans, when 650 mg of aspi-
rin is taken orally, the peak concentration in blood is 25 lg/ml
at 20 min after administration. The aspirin concentration
quickly decreases to less than 5 lg/ml at 2 h after administra-
tion. The peak concentration of salicylic acid, a derivative of
aspirin, is 45 lg/ml at 1 h after administration [12]. In this
study, we showed that aspirin inhibits the adhesion of Jurkat
T cells to AoSMC in a dose-dependent manner. This ﬁnding
indicates that lower concentrations of aspirin than used in this
study can prevent adhesion. Therefore, it is possible that lower
doses of aspirin may work to prevent the action of T lympho-
cytes at the inﬂammatory sites of arteries, especially when used
long-term. In inﬂammatory exudates, the clearance of salicy-
late was delayed, and the concentration was high enough for
physiological eﬀects, suggesting that aspirin works longer
locally at inﬂammatory sites [32].
In conclusion, aspirin prevents the adhesion of Jurkat T cells
to AoSMC through the inhibition of NF-jB activation and
adhesion molecule expression. These actions of aspirin on
VSMC may inhibit the formation of atherosclerotic plaques,
via suppression of the adhesion to inﬂammatory cells.
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